In:
Circulation: Cardiovascular Quality and Outcomes, Ovid Technologies (Wolters Kluwer Health), Vol. 12, No. Suppl_1 ( 2019-04)
Abstract:
Introduction: Aortic valve disease is the leading valvular pathology in the Western World. Transcatheter aortic valve implantation (TAVI) have emerged as alternatives to surgical aortic valve replacement (SAVR). The study’s objective is to describe clinical trends in TAVI and SAVR in patients with aorta valve disease. Method: Within the Netherlands Heart Registry (NHR) trends were analyzed in isolated TAVI and SAVR among 14 centers in the Netherlands. Results: Between 2013 and 2017, a total of 7432 isolated SAVR and 5929 TAVI procedures have been performed. An 43.9% (from 2174 to 3128) increase in the total number of SAVRs and TAVIs was observed, merely in het due to a 161% (from 669 to 1748) growth of TAVIs. In 2017, there was a slight decline in SVAR. In TAVI patients the 30-day and 120-day mortality decreased significantly, from 7.2% (40 of 558) and 10.6% (59 of 558) in 2013 to 3.4% (52 of 1540) and 5.7% (86 of 1509) in 2017 respectively. The risk adjusted outcomes showed a significant decrease in vascular complications in TAVI. The risk profile of TAVI patients has changed over time, with a trend towards decrease of risk: lower EuroSCORE and higher left ventricular ejection fraction. Conclusion: This registry showed a rapid increase in the use of TAVI for the treatment of aortic valve disease in the Netherlands. Importantly, early mortality rates declined as did the rate of complications. Furthermore, a trend towards decrease of risk was observed.
Type of Medium:
Online Resource
ISSN:
1941-7713
,
1941-7705
DOI:
10.1161/hcq.12.suppl_1.114
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2019
detail.hit.zdb_id:
2453882-6
